Nicox

New glaucoma therapy offers first drug option in years
Ocular surface involves more than lacrimal gland output, tear evaporation rateJoseph Tauber, MD, has found in his experience as an active clinical research that listening to patients may be the greatest diagnostic tool for ocular surface disease.
Valeant acquires Nicox’s US ophthalmic diagnostics subsidiaryValeant Pharmaceuticals International has acquired Nicox S.A.’s U.S. diagnostics subsidiary, Nicox, Inc., in a deal worth up to $20 million.
Valeant acquires Nicox Inc.Nicox S.A. announced that Valeant Pharmaceuticals has acquired Nicox’s U.S. diagnostics subsidiary Nicox Inc., in a deal worth up to $20 million.
Nicox acquires rights to anti-viral drop; buys French ophthalmic firmNicox S.A has agreed to acquire the Carragelose anti-viral eye drop program from Marinomed Biotechnologie GmbH of Austria. The acquisition will provide Nicox with an anti-viral ophthalmic product, expected to launch in Europe within 2 years and pending CE marking.
Nicox acquires rights to anti-viral drop; buys French ophthalmic firmNicox S.A has agreed to acquire the Carragelose anti-viral eye drop program from Marinomed Biotechnologie GmbH of Austria. The acquisition will provide Nicox with an anti-viral ophthalmic product, expected to launch in Europe within 2 years and pending CE marking.
Nicox to distribute acute conjunctivitis diagnostic test in JapanNicox S.A. has entered into an exclusive agreement with Nitto Medic for the distribution in Japan of AdenoPlus, a diagnostic test that aids in the differential diagnosis of acute conjunctivitis.
Diagnostic technologies enhancing patient quality of careAs technology continues to advance, the ability to serve patients will greatly improve. Having sophisticated tools at our disposal will make medical decisions all the more appropriate and treatment plans all the more effective.
Nicox launches expanded access to Sequenom’s RetnaGene tests in U.S.Nicox Inc. is launching expanded access to Sequenom Laboratories’ RetnaGene portfolio of genetic tests—RentaGene AMD and RetnaGene LR—which asses an individual’s risk for advanced age-related macular degeneration (AMD).
Sjögren’s syndrome screening may have major impact on dry eyeA new test for the diagnosis of Sjögren’s syndrome may change ophthalmic practices’ approach to the management of dry eye.